AGEN logo

AGEN Agenus Inc.

NASDAQ Capital Market · Biotechnology · Healthcare

$6.13
-0.27 (-4.14%)

Agenus Inc. is a clinical-stage biotechnology firm operating globally, dedicated to the discovery and development of immuno-oncology therapies. The company's innovative technological arsenal includes Retrocyte Display, a sophisticated antibody expression platform designed to identify fully human and humanized monoclonal antibodies, alongside other proprietary display technologies. Agenus is also a…

Market Cap: $277.59Mwww.agenusbio.com

Price

$6.96+78.01%
$2.88$4.69$6.49$8.30
Apr 30Aug 7

Social Signal Score

47
5d
—
30d
44
7 mentions
+0.0%
60d
46
11 mentions
+0.0%
90d
50
14 mentions
+0.0%
news: 14

Analyst Ratings

12 analysts
Buyconsensus
Strong Buy 0Buy 10Hold 2Sell 0Strong Sell 0
Avg price target$25+307.5%
Low $25Median $25High $25
Current Consensus

Revenue

$31.49M+464.71%
$1.64M$85.41M$169.18M$252.95M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-0.90
$-1.51–$-0.29
1 analysts
FY2026
$0.63
$0.58–$0.68
2 analysts
FY2027
$-0.54-186% YoY
$-0.84–$-0.23
2 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Garo H. Armen
Sector
Healthcare
Industry
Biotechnology
Employees
81
Beta
1.52
Country
US
Piotroski score
5 / 9 (Middling)
Altman Z-score
-10.26
www.agenusbio.com